Role of cetrorelix in the prevention and treatment of ovarian hyperstimulation syndrome: a prospective case control study
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20233289Keywords:
Cetrorelix, Gonadotropin releasing hormone antagonist, Ovarian hyperstimulation syndromeAbstract
Background: Ovarian hyperstimulation syndrome (OHSS) has intrigued clinicians for many years because of its devastating consequences. As an iatrogenic condition resulting from elective ovarian stimulation in the quest for pregnancy, the need to completely prevent the syndrome is evident. Gonadotropin releasing hormone (GnRH) antagonist Cetrorelix has found to be effective in treatment of OHSS and some studies have found it to be helpful in prevention of this condition. Hence, we designed a hospital-based study to investigate the effect of Cetrorelix in preventing and treating OHSS in in-vitro fertilization – embryo transfer (IVF–ET) patients at risk of OHSS undergoing long and short protocol.
Methods: The study includes total 102 patients undergoing controlled ovarian stimulation COS for IVF/ICSI. All cases were stimulated using long and short protocol. Depending on whether a GnRH antagonist was given after ovum pick-up (OPU) the patients were divided in two groups: Cetrorelix (antagonist) group (n=51) and control group (n=51). The study group was treated with Cetrorelix 0.25 mg for 5 days commencing on the day of ovum pick up.
Results: Incidence of mild OHSS was significantly higher (p=0.01) whereas moderate to severe OHSS was significantly lower in the antagonist group (p<0.05). None of the patients had critical OHSS.
Conclusions: GnRH antagonist Cetrorelix administration in early luteal phase in patients undergoing long or short protocol is effective in prevention and treatment of OHSS.
References
Abramov Y, Elchalal U, Schenker JG. An epidemic of severe OHSS; a price we have to pay? Hum Reprod. 1999;14:2181-3.
Marzal A, Holzer H, Tulandi T. Future developments to minimize ART risks. Semin Reprod Med. 2012;30:152-60.
Lyons CA, Wheeler CA, Frishman GN, Hackett RJ, Seifer DB, Haning RV, early and late resentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod. 1994;9:792-9.
Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:901-7.
Papanikolaou EG, Tournaye H, Verpoest W, Camus M, Vernaeve V, Van Steirteghem A, et al. Early and late ovarian hyperstimulation syndrome: Early pregnancy outcome and profile. Hum Reprod. 2005;20:636-41.
Xing W, Lin H, Li Y, Yang D, Wang W, Zhang Q. Is the GnRH Antagonist Protocol Effective at Preventing OHSS for Potentially High Responders Undergoing IVF/ICSI. PLoS One. 2015;10:e0140286.
Levy MJ, Ledger W, Kolibianakis EM, IjzermanBoon PC, Gordon K. Is it possible to reduce the incidence of weekend oocyte retrievals in GnRH antagonist protocols. Int J Reprod Biomed. 2013;26:50-8.
Griesinger G, Felberbaum R, Diedrich K. GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians’ second choice data from the German national IVF registry. Hum Reprod. 2005;20:2373-5.
Fouda UM, Sayed AM, Elshaer HS, Hammad BE, Shaban MM, Elsetohy KA, et al. GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial. J Ovarian Res. 2016;9:29.
Lainas T, Sfontouris I, Zorzovilis I, Petsas G, Lainas G, Kolibianakis E. Management of severe early ovarian hyperstimulation syndrome by reinitiation of GnRH antagonist. Reprod Biomed Online. 2007;15:408-12.
Navot D, Bergh PA, Laufer N. Ovarian Hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment. Fertil Steril. 1992;58:249-61.
Levine Z, Berin I. Severe ovarian hyperstimulation syndrome. In: Gardner D, Weissman A, Howles C, Shoham Z. Textbook of Assisted Reproductive Techniques: Volume 2: clinical perspectives. 5th ed. NewYork: CRC Press. 2018;820-39.
Chen C, Liu L, Geng Y, Yang C, Li T, Gao Y. Prevention and treatment of OHSS by administration of GnRH antagonist in the early luteal phase of controlled ovarioan hyperstimulation cycles. Int J Clin Exp Pathol. 2017;10(2):2193-8.
Lainas GT, Kolibianakis EM, Sfontouris IA, Zorzovilis IZ, Petsas GK, Tarlatzi TB, et al. Outpatient management of severe early OHSS by administration of GnRH antagonist in luteal phase: an observational cohort study. Reprod Biol Endocrinol. 2012;10:69-71.
Wang P, Ling XF, Li XL, Lu Y, Su Y, Zhang J, Zhao C. Application of gonadotropin releasing hormone antagonist in the prevention and treatment of ovarian hyperstimulation syndrome. Chin J Clinicians. 2013;7:8584-7.
Moses M, Bogowsky H, Anteby E, Lunenfeld B, Rabau E, Serr DM, et al. Thromboembolic phenomena after ovarian stimulation with menopausal gonadotropins. Lancet. 1965;2:1213.
Esteban–Altirriba J. Le syndrome d’hyperstimulation massive des ovaries. Rev Fr Gynecol Obstet. 1961;56:555.
Figueroa – Cases P. Reaccionovaricamonstruosa a las gonadotrofinas a proposito de un caso fatal. Ann Cirug. 1958;23:116.
Cluroe AD, Synek BJ. A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology. 1995;27:344-6.
Semba S, Moriya T, Youssef EM, Sasano H. An autopsy case of ovarian hyperstimulation syndrome with massive pulmonary edema and pleural effusion. Pathol Int. 2000;50:549-52.
Garcia-Velasco JA. How to avoid ovarian hyperstimulation syndrome: a new indication for dopamine agonists. Int J Reprod Biomed. 2009;18(2):71-5.
Ajonuma LC. Is vascular endothelial growth factor (VEGF) the main mediator in ovarian hyperstimulation syndrome (OHSS). Med Hypotheses. 2008;70:1174-8.
Asimakopoulos B, Nikolettos N, Nehls B, Diedrich K, Al-Hasani S, Metzen E. Gonadotropin releasing hormone antagonists did not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulose leutinized cell cultures. Fertil Steril. 2006;86(3):636-41.
Taylor PD, Hillier SG, Fraser HM. Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary. J Endocrinol. 2004;183(1):1-17.
Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Alexopoulou E, et al. Live births after management of severe OHSS by GnRH antagonist administration in the luteal phase. Reprod Biomed Online. 2009;19:789-95.
Bosch E, Valencia I, Escudero E, Crespo J, Simon C, Remohi J, et al. Premature luteinization during gonadotropin releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril. 2003;80:1444-9.
Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Iliadis GS, et al. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Int J Reprod Biomed. 2009;18:15-20.
Lainas G, Kolibianakis E, Sfontouris I, Zorzovilis I, Petsas G, Lainas T, et al. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS. Hum Reprod. 2013;28:1929-42.
Eftekhar M, Miraj S, Mortazavifar Z. The effect of luteal phase gonadotropin- releasing hormone antagonist administration on IVF outcomes in women at risk of OHSS. Int J Reprod Bio Med. 2016;14:507-10.
Papanikolaou EG, Tournaye H, Verpoest W, Camus M, Vernaeve V, Van Steirteghem A, et al. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod. 2005;20:636-41.
